BioCentury
ARTICLE | Clinical News

BioMarin shares spike on dwarfism data

June 19, 2015 1:19 AM UTC

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) gained $15.06 (12%) to an all-time high closing price of $138.66 on Thursday after it reported results post-market Wednesday from a Phase II study of vosoritide ( BMN 111) to treat achondroplasia. ...